Skip to content

Proto Labs PRLB Current maturities of long-term debt

Current maturities of long-term debt at other companies

West Pharmaceutical Services logo
West Pharmaceutical ServicesWST

Other financials

Income statement

See full
Revenue$139.3M+10.4%
Gross profit$63.6M+14.2%
Operating income$9.8M+117%
Net income$8.1M+125%
EPS (diluted)$0.33+120%

Balance sheet

See full
Cash & equivalents$124.0M+49.9%
Total debt$2.6M-16.6%
Total equity$683.1M+4.0%
Total assets$778.6M+5.6%

Cash flow

See full
Operating cash flow$17.5M-4.6%
CapEx$3.5M+181%
Free cash flow$14.0M-18.2%

Valuation

See full
Market cap$1.9B+59.7%

Profitability

See full
Gross margin44.9%+0.5pp
Operating margin5.6%+1.7pp
Net margin4.7%+1.6pp
FCF margin10.4%-3.1pp

Returns & leverage

See full
Return on equity3.8%+1.6pp
Debt / equity0.0×
Current ratio3.5×+0.4×

Where this comes from

Reported directly by Proto Labs in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.

The official record: Proto Labs’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Proto Labs's current maturities of long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Proto Labs's current maturities of long-term debt?
Proto Labs (PRLB) reported current maturities of long-term debt of $207K in Q1 2026.
How has Proto Labs's current maturities of long-term debt changed year-over-year?
Proto Labs's current maturities of long-term debt decreased by 33.7% year-over-year, from $312K to $207K.
What is the long-term trend for Proto Labs's current maturities of long-term debt?
Over 5 years (2020 to 2025), Proto Labs's current maturities of long-term debt has grown at a -12.3% compound annual growth rate (CAGR), from $552K to $286K.